Pemetrexed

Generic Name: Pemetrexed

Brand Names: Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁N_₅O_₆

CAS Number: 137281-23-3

Unique Ingredient Identifier: 04Q9AIZ7NO

Background: Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.

Indication: Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions: Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma

Associated Therapies: Monotherapy

Clinical Trials

Intra-pemetrexed Alone or Combined With Concurrent Radiotherapy for Leptomeningeal Metastasis

Not Applicable

Recruiting

Conditions: Leptomeningeal Metastasis

Interventions: Drug: Pemetrexed
Radiation: Radiotherapy

First Posted Date: 2022-03-31

Last Posted Date: 2022-09-30

Lead Sponsor: The First Hospital of Jilin University

Target Recruit Count: 100

Registration Number: NCT05305885

Locations: 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China

A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors

Phase 1

Active, not recruiting

Conditions: Advanced Cancer

Interventions: Biological: BMS-986406
Biological: Nivolumab
Drug: Carboplatin
Drug: Pemetrexed
Drug: Paclitaxel

First Posted Date: 2022-03-28

Last Posted Date: 2024-07-03

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 154

Registration Number: NCT05298592

Locations: 🇺🇸
Local Institution - 0021, Birmingham, Alabama, United States
🇺🇸
University California San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, California, United States

and more 26 locations

Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006)

Phase 3

Recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Biological: pembrolizumab/vibostolimab
Biological: durvalumab
Drug: cisplatin
Drug: pemetrexed
Drug: etoposide
Drug: carboplatin
Drug: paclitaxel
Radiation: thoracic radiotherapy

First Posted Date: 2022-03-28

Last Posted Date: 2024-12-19

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 784

Registration Number: NCT05298423

Locations: 🇨🇳
Tianjin Cancer Hospital ( Site 0329), Tianjin, Tianjin, China
🇨🇳
Hangzhou Cancer Hospital-Medical Oncology ( Site 0302), Hangzhou, Zhejiang, China
🇨🇳
The Second Affiliated hospital of Zhejiang University school of medicine ( Site 0301), Hangzhou, Zhejiang, China

and more 157 locations

Additional Chemotherapy for EGFRm Patients With the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)

Phase 2

Recruiting

Conditions: NSCLC Stage IV
NSCLC Stage IIIB

Interventions: Drug: Osimertinib
Drug: Pemetrexed
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2022-03-16

Last Posted Date: 2023-05-17

Lead Sponsor: Goethe University

Target Recruit Count: 50

Registration Number: NCT05281406

Locations: 🇩🇪
Universitätsklinik Köln, Lung Cancer Group Cologne - Innere Medizin I, Köln, Germany
🇩🇪
LMU-München Pneumologie und Thorakale Onkologie Medizinische Klinik V; Innenstadt, München, Germany
🇩🇪
Universitätsklinikum Hamburg-Eppendorf Hubertus Wald Tumorzentrum - UCCH II. Medizinische Klinik und Poliklinik, Hamburg, Germany

and more 11 locations

Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer

Phase 1

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Tislelizumab
Drug: Pemetrexed
Drug: Bevacizumab

First Posted Date: 2022-03-10

Last Posted Date: 2022-07-13

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT05273814

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

Phase 3

Recruiting

Conditions: Carcinoma
Non-Small-Cell Lung

Interventions: Drug: Pemetrexed
Drug: Savolitinib
Drug: Cisplatin
Drug: Osimertinib
Drug: Carboplatin

First Posted Date: 2022-03-02

Last Posted Date: 2024-12-13

Lead Sponsor: AstraZeneca

Target Recruit Count: 324

Registration Number: NCT05261399

Locations: 🇻🇳
Research Site, Ho Chi Minh, Vietnam

Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations

Phase 2

Active, not recruiting

Conditions: EGFR Activating Mutation
Non-squamous Non-small-cell Lung Cancer

Interventions: Drug: Pembrolizumab
Drug: Lenvatinib
Drug: Carboplatin
Drug: Pemetrexed

First Posted Date: 2022-02-28

Last Posted Date: 2024-08-28

Lead Sponsor: Juntendo University

Target Recruit Count: 30

Registration Number: NCT05258279

Locations: 🇯🇵
Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
🇯🇵
Saitama Cancer Center, Ina, Saitama, Japan
🇯🇵
Shizuoka Cancer Center, Nagaizumi-cho, Shizuoka, Japan

and more 7 locations

De-escalation Immunotherapy MAintenance Duration Trial for Stage IV Lung Cancer Patients with Disease Control After Chemo-immunotherapy Induction

Phase 2

Recruiting

Conditions: Metastatic NSCLC

Interventions: Drug: Pembrolizumab before randomization
Drug: Chemotherapy
Drug: Pemetrexed
Drug: Pembrolizumab after randomization

First Posted Date: 2022-02-24

Last Posted Date: 2024-10-18

Lead Sponsor: Intergroupe Francophone de Cancerologie Thoracique

Target Recruit Count: 1360

Registration Number: NCT05255302

Locations: 🇫🇷
Aix-en-Provence - CH, Aix-en-Provence, France
🇫🇷
Amiens - Clinique de l'Europe, Amiens, France
🇫🇷
Angers - CHU, Angers, France

and more 40 locations

Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)

Phase 2

Recruiting

Conditions: DLBCL

Interventions: Drug: Tislelizumab
Drug: Pemetrexed

First Posted Date: 2022-02-23

Last Posted Date: 2024-04-17

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 28

Registration Number: NCT05253118

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

Phase 1

Active, not recruiting

Conditions: Lung Neoplasm Malignant
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Disease
Carcinoma, Bronchogenic
Bronchial Neoplasms
Adenocarcinoma

Interventions: Drug: BLU-451
Drug: Carboplatin
Drug: Pemetrexed

First Posted Date: 2022-02-16

Last Posted Date: 2024-01-16

Lead Sponsor: Blueprint Medicines Corporation

Target Recruit Count: 332

Registration Number: NCT05241873

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California, United States
🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan

and more 20 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy